| Literature DB >> 32847525 |
Masamitsu Morishita1, Yukio Maruyama2, Masatsugu Nakao2, Nanae Matsuo2, Yudo Tanno2, Ichiro Ohkido2, Masato Ikeda2, Takashi Yokoo2.
Abstract
BACKGROUND: Chronic kidney disease-mineral and bone disorder (CKD-MBD) management in patients with end-stage renal disease is important owing to the risk of cardiovascular diseases. In clinical practice, we manage patients not by monitoring the levels of biologically active ionized calcium (iCa) but by monitoring total serum calcium or corrected calcium (cCa). We previously reported that iCa/cCa ratio was different between patients with hemodialysis and those with peritoneal dialysis (PD). In PD patients, several factors are expected to affect iCa/cCa ratio. Therefore, modifying the strategy to achieve better CKD-MBD management might be necessary; however, no reports have studied this to date. Therefore, we investigated the factors influencing iCa/cCa ratio in PD patients.Entities:
Keywords: Acid–base equilibrium; Chronic kidney disease-mineral and bone disorder; Corrected calcium; Ionized calcium; Peritoneal dialysis; Residual renal function
Year: 2020 PMID: 32847525 PMCID: PMC7448483 DOI: 10.1186/s12882-020-02033-y
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Patient selection flowchart. Abbreviations: PD, peritoneal dialysis; HD, hemodialysis
Baseline characteristics of the 169 PD patients in our study cohort
| Variable | No. of Missing Value (%) | Whole patients | iCa/cCa ratio | |||
|---|---|---|---|---|---|---|
| < 47.0% | 47.0 to < 49.0% | ≥49.0% | ||||
| Number | 0 (0) | 169 | 56 (33%) | 54 (32%) | 59 (35%) | |
| Male [%] | 0 (0) | 124 (73%) | 40 (71%) | 37 (69%) | 47 (80%) | 0.38 |
| Age [y] | 0 (0) | 62 ± 13 | 63 ± 13 | 61 ± 14 | 61 ± 14 | 0.56 |
| PD duration [months] | 0 (0) | 24 (11–50) | 32 (12–74) | 24 (12–44) | 18 (9–40) | 0.04 |
| BMI [kg/m2] | 0 (0) | 23.7 ± 4.3 | 22.9 ± 4.1 | 23.8 ± 4.8 | 24.5 ± 4.0 | 0.14 |
| Underlying disease | 0.89 | |||||
| CGN [%] | 0 (0) | 50 (30%) | 16 (28%) | 18 (33%) | 16 (27%) | |
| Diabetes [%] | 0 (0) | 61 (36%) | 21 (38%) | 21 (39%) | 19 (32%) | |
| Nephrosclerosis [%] | 0 (0) | 29 (17%) | 11 (20%) | 6 (11%) | 12 (20%) | |
| PCKD [%] | 0 (0) | 6 (4%) | 1 (2%) | 2 (4%) | 3 (5%) | |
| Others or unknown [%] | 0 (0) | 23 (14%) | 7 (13%) | 7 (13%) | 9 (15%) | |
| Comorbidity | ||||||
| CVD [%] | 0 (0) | 52 (31%) | 19 (34%) | 22 (41%) | 11 (19%) | 0.03 |
| Residual renal function | ||||||
| Urine volume [ml] | 25 (14.8) | 700 (300–1500) | 500 (200–1080) | 600 (190–1420) | 900 (540–1730) | 0.01 |
| Weekly renal Kt/V | 49 (29.0) | 0.46 (0.14–0.83) | 0.25 (0.09–0.61) | 0.43 (0.12–0.73) | 0.66 (0.40–1.00) | < 0.01 |
| PD solution | ||||||
| Dialysate Volume [L] | 0 (0) | 5.8 ± 1.8 | 6.3 ± 1.5 | 5.7 ± 1.9 | 5.5 ± 1.9 | 0.045 |
| Medication | ||||||
| Cinacalcet [%] | 0 (0) | 47 (28%) | 23 (41%) | 13 (24%) | 11 (19%) | 0.02 |
| Vitamin D [%] | 0 (0) | 91 (54%) | 27 (48%) | 29 (54%) | 35 (59%) | 0.49 |
| Ca-containing P binder [%] | 0 (0) | 47 (28%) | 23 (41%) | 10 (19%) | 14 (24%) | 0.02 |
| Ca-free P binder [%] | 0 (0) | 86 (51%) | 26 (46%) | 37 (69%) | 23 (39%) | < 0.01 |
| Laboratory data | ||||||
| pH | 0 (0) | 7.34 ± 0.04 | 7.366 ± 0.033 | 7.339 ± 0.005 | 7.328 ± 0.005 | < 0.01 |
| Bicarbonate [mmol/L] | 0 (0) | 24.8 ± 2.5 | 25.3 ± 2.5 | 24.7 ± 2.3 | 24.3 ± 2.5 | 0.08 |
| Hemoglobin [g/dL] | 2 (1.2) | 11.2 ± 1.3 | 10.8 ± 1.5 | 11.1 ± 1.1 | 11.6 ± 1.2 | < 0.01 |
| Creatinine [mg/dL] | 0 (0) | 10.4 ± 3.2 | 10.7 ± 2.8 | 11.1 ± 3.6 | 9.6 ± 2.9 | 0.04 |
| Albumin [g/dL] | 0 (0) | 3.3 ± 0.5 | 2.9 ± 0.4 | 3.4 ± 0.5 | 3.5 ± 0.3 | < 0.01 |
| Phosphorus [mg/dL] | 0 (0) | 5.4 ± 1.3 | 5.4 ± 1.2 | 5.5 ± 1.6 | 5.4 ± 1.0 | 0.84 |
| Total Ca [mg/dL] | 0 (0) | 8.7 ± 0.7 | 8.5 ± 0.7 | 8.6 ± 0.6 | 8.9 ± 0.6 | < 0.01 |
| cCa [mg/dL] | 0 (0) | 9.4 ± 0.7 | 9.6 ± 0.8 | 9.3 ± 0.6 | 9.3 ± 0.6 | 0.02 |
| iCa [mmol/L] | 0 (0) | 1.13 ± 0.09 | 1.09 ± 0.09 | 1.12 ± 0.07 | 1.18 ± 0.07 | < 0.01 |
| aiCa [mg/dL] | 0 (0) | 4.5 ± 0.4 | 4.6 ± 0.3 | 4.4 ± 0.4 | 4.4 ± 0.4 | < 0.01 |
| iCa/cCa ratio [%] | 0 (0) | 48.2 ± 2.5 | 45.4 ± 1.5 | 48.1 ± 0.6 | 50.7 ± 1.4 | < 0.01 |
| Intact PTH [pg/dL] | 0 (0) | 176 (103–255) | 180 (111–269) | 177 (121–264) | 151 (85–233) | 0.54 |
| CRP [mg/dL] | 0 (0) | 0.12 (0.05–0.36) | 0.22 (0.05–0.43) | 0.12 (0.05–0.32) | 0.08 (0.04–0.23) | 0.06 |
Abbreviations: PD peritoneal dialysis, BMI body mass index, CGN chronic glomerulonephritis, PCKD polycystic kidney disease, CVD cardiovascular disease, Ca calcium, cCa corrected calcium, iCa ionized calcium, PTH parathyroid hormone, CRP C-reactive protein
aiCa levels represented as mg/dL; these are the same data as above in mmol/L.
Fig. 2Relationship between iCa/cCa ratio and weekly renal Kt/V. iCa/cCa ratio and weekly renal Kt/V were directly correlated in all 169 study patients (r = 0.41, p < 0.01). The lower the RRF, the lower the iCa/cCa ratio in the subjects in this study
Fig. 3Relationship between iCa and cCa in higher and lower weekly renal Kt/V groups. In both groups, iCa and cCa were directly correlated (r = 0.80, p < 0.01 and r = 0.86, p < 0.01 for the higher and lower renal Kt/V groups, respectively). At the same cCa levels, patients with lower RRF had lower iCa levels than those with higher RRF
Multiple regression analysis of iCa/cCa ratio
| Variable | Regression coefficient | Standard error | t value | 95% CI | |
|---|---|---|---|---|---|
| PD duration a | −0.00159 | 0.00210 | −0.75 | 0.45 | −0.00574–0.00257 |
| Renal Kt/V a | 0.00579 | 0.00203 | 2.86 | < 0.01 | 0.00177–0.00982 |
| pH | −0.246 | 0.045 | −5.42 | < 0.01 | −0.336−− 0.157 |
| Hemoglobin | 0.00149 | 0.00132 | 1.13 | 0.26 | −0.00111–0.00410 |
| Creatinine | −0.000558 | 0.000752 | 0.46 | 0.46 | −0.000928–0.00205 |
| Phosphate | −0.00305 | 0.00167 | −1.82 | 0.07 | −0.00635–0.000250 |
| Dialysate volume a | −0.00131 | 0.00547 | −0.24 | 0.81 | −0.0121–0.00949 |
aPD duration, weekly renal Kt/V, and dialysate volume are log-transformed
Abbreviation: PD peritoneal dialysis